Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Eligibility criteria
Qualifiers
Diagnosis of MDS, or a clinical suspicion for a new diagnosis of MDS, for whom routine diagnostic testing is requested or planned to be requested.
Seen in the outpatient setting.
Not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents).
Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
Disqualifiers
None
Trial design
Treatments tested in this trial
- ChromoSeq
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
American Society of Hematology
Collaborator
Edward P. Evans Foundation
Collaborator
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov